Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03678948
Other study ID # 2018H0244
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 8, 2018
Est. completion date February 8, 2021

Study information

Verified date September 2021
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the changes in clinical and imaging outcomes following arthroscopic treatment of chondral lesion(s) by Radiofrequency-Based debridement or Mechanical Debridement in subjects 18-50 years of age.


Description:

This is a non-inferiority, prospective, single blinded, randomized, single-center study design with enrollment of 82 randomized subjects (to assure 70 subjects complete the study). The sample size of 82 participants was calculated from a power analysis. The study was powered to detect at least a seven point change in KOOS pain score based on achieving 80% statistical power to detect a non-inferiority margin. Study duration will be until the last subject enrolled reaches 52 weeks post-operative. The 82 randomized subjects will be randomized at a 1:1 ratio into the Werewolf Coblation wand treatment group or mechanical debridement treatment group. Subjects will be blinded to their treatment assignment until they complete all study visits. Upon withdraw from the study, termination from the study, or new or recurrent symptoms requiring a subsequent arthroscopy, the blinded assignment will be revealed to the subject.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date February 8, 2021
Est. primary completion date February 8, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Given written informed consent on the IRB approved consent form specific to the study, prior to study participation - 18-50 years old - Male or Female - Suspected chondral damage in the following locations where debridement is indicated: - Medial femoral condyle - Lateral femoral condyle - Trochlea - Patella - < 30% joint space narrowing as seen on x-ray (merchant view, AP and PA Rosenberg) - 1 or more chondral lesion(s) as noted on MRI Exclusion Criteria: - Previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable) - Focal chondral defect indicated for concomitant procedures (i.e., microfracture, ACI, MACI, OATs) - Concomitant procedures that are not allowed: - Lateral retinacular release - Excision of osteophytes - Subchondroplasty - Manipulation under anesthesia - ACL reconstruction - Quad tendon repair - Patellar tendon repair - Patellar tendon debridement - Multiligament reconstruction - Pregnant and/or intending to become pregnant during this study period

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Radiofrequency-Based Debridement
In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
Mechanical Debridement
Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement

Locations

Country Name City State
United States The Ohio State University Wexner Medical Center Jameson Crane Sports Medicine Institute Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Christopher Kaeding Smith & Nephew, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Knee and Osteoarthritis Outcome Scores (KOOS) activity subscale The previous week is the time period considered when answering the questions. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. change from baseline at week 52 post-op
Secondary Visual Analogue Scale (VAS) Using a ruler, the score is determined by mea-suring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. change from baseline at week 52 post-op
Secondary International Knee Documentation Committee (IKDC) subjective knee evaluation change from baseline at week 52 post-op
Secondary International Knee Documentation Committee (IKDC) objective knee change from baseline at week 52 post-op
Secondary Marx Activity Rating Scale (MARS) MARS includes 4 items that assess the frequency of running, cutting, decelerating, and pivoting based on the subjects "healthiest and most active state in the past year." A higher score indicates more functional demand on the knee joint and potentially a higher risk of injury. Each item is scored on a 5-point ordinal scale ranging from 0 (less than 1 time in a month) to 4 (4 or more times in a week), and the total scale score is obtained by summing the individual items' scores (range, 0-16). change from baseline at week 52 post-op
Secondary Work Productivity and Activity Impairment (WPAI V2.0) Asks about the effect of patient knee injury on their ability to work and perform normal daily activities change from 1 week post op to 6 weeks post-op
Secondary MRI Baseline MRI will be compared to MRI at 52 weeks to evaluate knee morphology, cartilage signal, osteophytes, bone marrow edema, subarticular cysts, effusions and loose bodies. The international cartilage repair score will be used. change from baseline at week 52 post-op
See also
  Status Clinical Trial Phase
Recruiting NCT04840147 - A Comparison of JointRep® and Microfracture in Repair of Cartilage Lesions on the Femoral Condyle or Trochlea, N/A
Recruiting NCT03588975 - A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee Phase 3
Completed NCT01076673 - Effect of Autologous Peripheral Blood Stem Cell Treatment on Articular Cartilage Regeneration Phase 2
Terminated NCT05082831 - Human ECM Implanted Within Microfracture Interstices & the Cartilage Defect in the Knee to Regenerate Hyaline Cartilage Phase 1
Withdrawn NCT05300490 - Prednisolone Urinary Excretion Kinetics
Recruiting NCT05924763 - The Clinical Outcome of BiCRI in the Treatment of Chondral and Osteochondral Lesions N/A
Completed NCT02118519 - Mesenchymal Stem Cells in Knee Cartilage Injuries Phase 2
Active, not recruiting NCT02524509 - the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee Phase 4
Completed NCT01576159 - Serum Cartilage Oligomeric Matrix Protein Levels After 12 Weeks of Different Exercises Phase 0
Completed NCT03101163 - Efficacy and Safety Study of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee Phase 2